Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 0690)

PROFIT WARNING

This announcement is made by Uni-Bio Science Group Limited ("**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors ("**Directors**") of the Company ("**Board**") wishes to inform the shareholders of the Company ("**Shareholders**") and potential investors that, based on a preliminary review and analysis on the unaudited consolidated management account of the Group for the financial year ended 31 December 2017, the latest discounted cashflow forecast over the pipeline products of the Company and information presently available to the Board, the Group is expected to record a substantial increase in loss for the year ended 31 December 2017 as compared to a loss of approximately HK$55,727,000 recorded by the Group for the year ended 31 December 2016. Such substantial increase in loss was mainly attributable to the impairment losses in the fair value of the Group's intangible assets generated from the development of pipeline products and product technology in the past. Due to the recent changes in the regulations of the pharmaceutical industry in the People's Republic of China and changes in the competitive landscape of the Group's pipeline projects, including a number of new players successfully entered into the market, the Group has therefore made relevant adjustments to the sales forecast of the current pipeline projects. In addition, the Board has decided to direct all the existing resources to develop an advanced formulation according to the Group's next-generation development plan after much cogitation with weighing all the consequences of action taken.

* *For identification purposes only*

The Board wishes to emphasis that the respective impairment losses are non-cash in nature which do not affect working capital sufficiency of the Group. The Company is still in the process of finalising its discounted cashflow forecast over the pipeline products and the consolidated financial statements for the year ended 31 December 2017. The information contained in this announcement is only based on the preliminary assessment made by the Board with reference to the information currently available, which has not been reviewed or audited by the auditors of the Company and may be subject to change. Shareholders and potential investors are advised to refer to the details of the Group's financial results for the year ended 31 December 2017, which are expected to be published in late March 2018 and the subsequent publication of the Group's annual report for the year ended 31 December 2017.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 9 March 2018

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Kingsley Leung (Chairman) and Mr. Chen Dawei (Vice-chairman); one non-executive Director, Ms. Lau Chau In and three independent non-executive Directors, namely, Mr. Zhao Zhi Gang, Mr. Chow Kai Ming and Mr. Ren Qimin.